KALA BIO, Inc. announced its financial results for the first quarter ended March 31, 2025, on May 14, 2025. The company reported cash resources of $42.2 million as of March 31, 2025. These funds are expected to support operations into the first quarter of 2026, maintaining the previously stated cash runway.
The company continued to make progress in its Phase 2b CHASE trial for KPI-012, its lead product candidate for Persistent Corneal Epithelial Defect (PCED). Patient enrollment was ongoing during the quarter, with topline data from the trial still anticipated in the third quarter of 2025. This timeline is consistent with the update provided in the previous quarter's report.
As a clinical-stage biopharmaceutical company, KALA remains focused on the research and development of innovative therapies for rare and severe eye diseases. The continued advancement of KPI-012, which holds Orphan Drug and Fast Track designations, is central to the company's strategy. The financial update underscores the ongoing capital requirements for its clinical development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.